Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Shionogi Enter Drug Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Shionogi Enter Drug Discovery Pact

Evotec AG and Shionogi & Co Ltd. have entered a fragment-based drug discovery alliance to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG and Shionogi & Co Ltd. have entered a fragment-based drug discovery alliance to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi. Evotec will apply its integrated fragment-based drug discovery platform, EVOlution. The platform, used for the selection of target-specific strategies, combines biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography. Financial details were not disclosed.

Dr. Mario Polywka, chief operating officer of Evotec said, “We are extremely pleased that Shionogi
has decided to undertake these projects with Evotec. Our proprietary fragment-
based drug discovery platform has shown that it adds significant value to our partner´s programs and we look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics